Enveric Biosciences Inc./$ENVB

1D1W1MYTD1Y5YMAX

About Enveric Biosciences Inc.

Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.
Ticker
$ENVB
Sector
Health
Primary listing
NASDAQ
Employees
6
Headquarters
Cambridge, United States
Website
www.enveric.com

ENVB Metrics

BasicAdvanced
$7.3M
-
-$7.48
1.11
-

ENVB News

AllArticlesVideos

Enveric Biosciences Reports Financial Results and Provides Corporate Update for Second Quarter 2026

Business Wire1 month ago

Enveric Biosciences Says New Preclinical Data Confirms Non-Hallucinogenic Profile For Lead Psychiatric Candidate

Benzinga1 month ago

Enveric Biosciences Welcomes Final FDA Guidance for Psychedelic Drug Development

Business Wire2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.